8-K
filed June 14, 2023, 7:59 PM ET
ticker STRO
CIK 0001382101
other material
confidence high
sentiment negative
materiality 0.75
BMS terminates collaboration on CC-99712; Sutro regains full rights
SUTRO BIOPHARMA, INC.
- BMS notified Sutro on June 9, 2023 of termination of Amended Collaboration and License Agreement for CC-99712.
- Termination effective October 7, 2023; decision attributed to BMS portfolio prioritization.
- After termination, Sutro regains sole worldwide rights to the BCMA-targeting antibody-drug conjugate program.
- No financial terms, termination payments, or immediate impact on cash runway disclosed.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
3. Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 39,146,793 9,377,370 17,368 4,402,194
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
On June 8, 2023, the Company held its 2023 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of three Class II directors, identified in the table below, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes William J. Newell 39,690,178 8,851,353 4,402,194 Connie Matsui 29,080,240 19,461,291 4,402,194 James Panek 31,714,990 16,826,541 4,402,194
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Abstaining Broker Non-Votes 52,888,041 42,108 13,576 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions at the 2023-06-08 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
4. Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions: Shares For Shares Against Shares Abstaining Broker Non-Votes 43,016,509 5,507,942 17,080 4,402,194
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.